P/B
—
Guardant Health
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
$23.9B
Market Cap • 10/27/2026
2011
(15 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
20,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
23,9B
EV
24,5B
EV/Revenue
20,7
EV/EBITDA
-56,8
EV/EBIT
-52,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-1,4%
Total Yield
-1,4%
Payout
0%
Retained Earnings
-3,2B
Profitability
Gross Margin
65%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
31,8%
Capex/Revenue
4,7%
Capex/D&A
144,4%
Capex/OCF
-30%
SBC/OCF
—
% PPE
15,8%
% Goodwill
4%
ROE
171,6%
ROIC
—
Growth
CAGR Revenue 5Y
29,6%
CAGR Op. Income 5Y
4,9%
CAGR Net Income 5Y
4,2%
CAGR EPS 5Y
-1,5%
CAGR OCF 5Y
4,8%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
4
Quick Ratio
3,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!